| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0065 | 0.9 |
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | -0.0068 | 0.9 |
| mRNA | OSI-027 | CTRPv2 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | FSC231 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.9 |
| mRNA | BRD-K04800985 | CTRPv2 | pan-cancer | AAC | -0.0062 | 0.9 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | 0.0067 | 0.9 |
| mRNA | TPCA-1 | CTRPv2 | pan-cancer | AAC | -0.0052 | 0.9 |
| mRNA | triptolide | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | BRD-K79669418 | CTRPv2 | pan-cancer | AAC | 0.008 | 0.9 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.0055 | 0.9 |